Aurobindo Pharma gets FDA approval for generic equivalent of Xarelto
The anticoagulant drug, which has an estimated US market size of $447 million, is set to be launched in the first quarter of the 2025-26 fiscal.
13 April, 2025•2 min
0
13 April, 2025•2 min
0
Getting your Trinity Audio player ready...
More in Business
Business
NSE’s IPO bankers likely to run into a seller problem
Many of its 186,000 eligible shareholders are unlikely to sell their stock in the upcoming offer-for-sale—opting to resist formal price discovery and wait it out instead.
You may also like
Business
Has Aurobindo Pharma left its wild swings behind?
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
Business
Is Aurobindo Pharma the most underrated pharma company?
The Hyderabad-based generics maker is now India’s largest supplier of off-patent medicines to the US.